Brofoxine is a progesterone receptor modulator with anti-anxiety properties.

BRD4 ligand 15 (compound 5) is a BRD4 ligand and alkyne-modified chalcone derivative, which serves as a building block for the synthesis of BRD4-targeting PROTAC TKP-5.

Bradanicline (TC-5619) tosylate is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline tosylate exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline tosylate possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline tosylate requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline tosylate is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough.

BODIPY TMR PI(4,5)P2 ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PS ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PI ester ammonium is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BODIPY TMR Lyso PE ester is a lipid that can be used to prepare lipid nanoparticles (LNPs) for drug delivery.

BMY-30047 is a retinoic acid derivative. BMY-30047 has topical retinoid activity. BMY-30047 has relative low local and systemic toxicity.

BMS-520 is a potent, orally active and selective sphingosine-1-phosphate 1 (S1P1) agonist with an EC50 of 0.47nM. BMS-520 shows ~3400-fold selectivity over S1P3. BMS-520 demonstrates impressive efficacy in a rat model of arthritis and in a mouse experimental autoimmune encephalomyelitis (EAE) model of multiple sclerosis. BMS-520 can be used for arthritis and EAE research.

BMS-135 is a potenr, selective and ATP-competitive casein kinase 2 (CK2) inhibitor with IC50 of 0.8 and 0.3 nM for CK2αandCK2α′ isoforms. BMS-135 can simulate the structure of ATP and bind to the active pocket of CK2, thereby inhibiting its serine/threonine phosphorylation function. BMS-135 can inhibit cells proliferation and shows anti-tumor effect. BMS-135 can be used for research of colon cancer.

BL20-MMAE is an antibody-drug conjugate targeting ROR1, which is formed by conjugating an anti-ROR1 antibody with the Auristatin payload MMAE via a BL20 linker.

Bisdisulizole disodium is an organic chromophore with large near UV absorption cross section. Solutions of Bisdisulizole disodium dissolved in polar solvents show a strong, broad UV absorption feature centered at 340 nm.

Benzyl m-hydroxycarbanilate (Compound 9) is a biologically active chemical substance and also an intermediate.

Belotecan-GFGG is an intermediate. Belotecan-GFGG can be used to synthesize the peptide conjugate MI-6PEG-GGFG-Belotecan. Belotecan-GFGG can be used in the research of the tumor microenvironment.

Bcl-2-IN-24 (Compound 11g) is an efficient and selective Bcl-2 inhibitor with a Kd value of 11.3 μM. Bcl-2-IN-24 exhibits anti-proliferative activity against HCT-116 cells and A549 cells. Bcl-2-IN-24 effectively inhibits the colony-forming ability of tumor cells and induces cell apoptosis. Bcl-2-IN-24 can be used for research on colon cancer and lung cancer.

BC-3205 hydrochloride is an anti-amoeba agent. BC-3205 hydrochloride inhibits N. fowleri.

Azide-PEG2-amide-C14-COOH (Compound LP-379-p) is a lipid-containing compound. Azide-PEG2-amide-C14-COOH facilitates the delivery of oligonucleotide-based reagents to certain cell types or adipose tissue.

Azide-PEG12-Val-Arg-PAB is an ADC Linker and can be used for synthesis of ADCs.

Azide-C5-amide-tri-SA-bis(amide-PBA) (compound 15) is a linker targeting eye tissue specific protein, can be used for oligonucleotide coupling .

Azapetine is an α-adrenergic receptor antagonist, with a IC50 of 0.205 μM against rat α1-adrenergic receptors and a IC50 of 1.3 μM against rat α2-adrenergic receptors. Azapetine blocks α1/α2-adrenergic receptor-mediated contraction of blood vessels and vascular smooth muscles. Azapetine can be used for the research of peripheral vascular diseases.

ATR-IN-31 is a selective ATR kinase inhibitor with an IC50 of 7 nM. ATR-IN-31 does not significantly inhibit ATM kinase activity. ATR-IN-31 functionally inhibits ATR kinase activity. ATR-IN-31 inhibits viability of prostate cancer cells.ATR-IN-31 can be used for the research of prostate cancer.

AT1R antagonist 4 (Example 26) is an AT1R antagonist. AT1R antagonist 4 shows excellent antagonistic activity against calcium influx in cells stably expressing AT1 receptors and ETA receptors. AT1R antagonist 4 can be used in kidney disease research.

Aromatase-IN-8 is a selective Aromatase inhibitor against an IC50 of 0.05 µM. Aromatase-IN-8 exhibits selective antiproliferative effects against estrogen receptor-positive breast cancer cell lines, while showing no toxicity toward non-tumoral cells. Aromatase-IN-8 suppresses estrogen active, increases testosterone levels, and downregulates estrogen receptor expression and phosphorylation. Aromatase-IN-8 can be used for triple negative breast cancer research.

AQ-13 (Compound 7) is a Chloroquine analogue with anti-breast cancer property. AQ-13 shows antiproliferative activities against MDA-MB231 and MCF7 with GI50 of 27.81 and 17.85 μM. AQ-13 shows low cytotoxicity against non-cancerous breast epithelial cells MCF10A (GI50 = 65.26 μM). AQ-13 can be used for the research of breast cancer.

Apoptosis inducer 56 is an apoptosis inducer. Apoptosis inducer 56 induces DNA damage (upregulation of γH2AX and p-ATM expression) by minor groove binding. Apoptosis inducer 56 induces intrinsic apoptosis (upregulation of p53 and Bax/Bcl-2 ratio, cleaved caspase-7) via S-phase cell cycle arrest. Apoptosis inducer 56 shows selectivity for cancer cells over normal breast epithelial cells. Apoptosis inducer 56 can be used for the research of breast cancer.

AP21998 is a Fv (mutant FKBP) domain-selective ligand that binds to a single FKBPv. AP21998 disrupts FKBP-mediated oligomerization, blocks the proliferation of transformed myeloid progenitors and facilitates their terminal myeloid differentiation. AP21998 disrupts aggregates of CAD-hM1 receptor fusion protein, allowing receptors to exit the ER and enter the plasma membrane. AP21998 can be used for cancer research.

Antiviral agent 75 (example D26) is a Ebolavirus (EBOV) and Bundibugyo ebolavirus (BDBV) inhibitor with IC50s of 0.11 μM and 0.75 μM, respectively. Antiviral agent 75 can be used for the study of filovirus infection.

Antitumor agent-212 is a α-exo-methylene-selenolactone derivative with prominent selective antitumor activity. Antitumor agent-212 exhibits an MIC value of 128 μg/mL against Gram-positive bacteria. Antitumor agent-212 exhibits significant antitumor effects in the U87 human glioma xenograft model. Antitumor agent-212 can be used for the study of glioma, breast cancer and non-small cell lung cancer, and antibacterial study.

Anti-Trypanosoma cruzi agent-9 is a topoisomerase II inhibitor. Anti-Trypanosoma cruzi agent-9 inhibits the growth of Trypanosoma cruzi and Leishmania donovani.

Antiproliferative agent-76 (Compound II-2) is an 8-sulfonamidoquinoline derivative and a selective anticancer agent. Antiproliferative agent-76 blocks the NF-κB and WNT signaling pathways. Antiproliferative agent-76 promotes cancer cell Apoptosis. Antiproliferative agent-76 exhibits anticancer activity against colorectal cancer and leukemia.